Article
Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the EGFR T790M Mutation After Failure of Initial EGFR-TKI Treatment.
Anticancer research - 1 Sept 2018
Furuta Hiromi, Uemura Takehiro, Yoshida Tatsuya, Kobara Makiko, Yamaguchi Teppei, Watanabe Naohiro, Shimizu Junichi, Horio Yoshitsugu, Kuroda Hiroaki, Sakao Yukinori, Yatabe Yasushi, Hida Toyoaki
Abstract excerpt
BACKGROUND/AIM: The aim of this study was to evaluate the safety and efficacy of osimertinib for elderly patients, since the data remain limited. PATIENTS AND METHODS: A total of 77 patients with advanced non-small cell lung cancer (NSCLC) harboring the epidermal growth factor receptor (EGFR) T790M mutation and treated with osimertinib were reviewed. Efficacy and safety indicators, such as EGFR-tyrosine kinase...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.